BioNTech's Third Quarter: A Profit Forecast, a Missed Endpoint, and the Gap Between Them
Published on 11/02/2026 at 19:11 | Editorial boerse-global.de
BioNTech reports third-quarter 2026 results on 3 November, and the consensus has already sketched the shape of the numbers: EUR 1.05 billion in revenue and EUR 0.78 in earnings per share. On the surface that marks a return to profit after a bruising prior quarter, when the company booked EUR 105.6 million in sales and a loss of EUR 2.22 per share. The swing would be striking. It would also be measured against a low bar.
That is the first thing to hold in mind. The same consensus points to a 30.92% decline in revenue versus the year-earlier quarter. Both readings are correct, and they answer different questions. Sequentially, the business is recovering from a weak patch; year over year, it is still shrinking at a steep clip. Anyone who watches only the quarter-on-quarter improvement risks mistaking a rebound for a growth trend. A single solid quarter does not establish one.
The financial picture is only half of what investors will be weighing. The other half arrived in mid-October, when BNT113 — the company's experimental mRNA cancer immunotherapy — failed to clear the first of two primary endpoints in the Phase 2/3 AHEAD-MERIT trial. According to media reports, the study missed progression-free survival in HPV-driven head and neck cancer on 13 October. A better income statement does not undo that result, and it would be a mistake to let one blur the other. Revenue and clinical readouts answer separate questions; higher sales in a reporting period are no retroactive proof that a drug candidate works.
A Mixed Set of Signals From the Cancer Pipeline
BNT113 is not the only program drawing scrutiny. Two other cancer studies have already reported results with caveats attached. In the Phase 3 DYNASTY-Breast02 trial, BioNTech and DualityBio met the primary endpoint with trastuzumab pamirtecan — the progression-free survival advantage over chemotherapy was statistically significant by the companies' account, but modest in magnitude. Overall survival data were not yet mature, and both partners conceded that the benefit for patients in the current treatment landscape could be limited. They said they would discuss next steps.
Should investors sell immediately? Or is it worth buying BioNTech?
The picture brightens somewhat with pumitamig. Combined with docetaxel, the candidate produced a confirmed objective response rate of 36.7%, with early median progression-free survival of 6.9 months. Those data come from the Phase 2 ROSETTA Lung-107 study in patients with metastatic non-small cell lung cancer following first-line immunotherapy and chemotherapy, and were presented at the ESMO Congress 2026.
BioNTech and Bristol Myers Squibb are running that program together. A separate alliance took shape roughly two weeks ago, when BioNTech and Gilead signed a clinical collaboration and supply agreement. The partners will test pumitamig alongside sacituzumab govitecan in a global Phase 3 trial for first-line treatment of locally advanced or metastatic triple-negative breast cancer with low or absent PD-L1 expression. BioNTech will lead the study; Gilead will supply the drug.
What the Analyst Community Is Saying
Sentiment on the equity remains constructive, if not unanimous. Of 21 recommendations, 14 are buys and seven are holds. That is a favorable spread, though it is no substitute for comparing the actual quarterly figures and the corporate update against expectations.
Management has scheduled a conference call for 14:00 Central European Time on 3 November, alongside the financial results and a business update. For shareholders, the earnings arithmetic will matter — but so will how executives frame operational progress, particularly in light of the October setback.
The two threads deserve to be kept apart. A positive financial report is worth acknowledging on its own terms. A broader re-rating, though, would need more than a consensus-beating quarter; it would require convincing commentary on where the pipeline stands after a mixed run of readouts. Tomorrow's release can demonstrate financial improvement. Whether it marks a genuine turning point depends on whether the operational story gains clarity alongside the numbers.
Ad
BioNTech Stock: New Analysis - 2 November
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
